JPRN-UMIN000023710招募中未知
A multicenter, single arm phase 2 study to examine efficacy and cerebrospinal fluid transitivity of Osimertinib in leptomeningeal carcinomatosis (LMC) patients with non-small cell lung cancer harboring EGFR mutation - A phase 2 study of Osimertinib in LMC
HANSHI0 个研究点目标入组 15 人开始时间: 2016年10月1日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with interstitial pneumonia or lung fibrosis clearly demonstrated by chest CT 2.Patients with a history of serious drug allergy 3.Patients with any serious infectious disease or other serious concurrent medical condition (e.g., gastrointestinal hemorrhage) 4.Patients with high amount of or uncontrollable pleural effusion, ascites or pericardial effusion -If patients treat synechia with anticancer drugs who can participate in the study 5.Patients with any clinically problematic heart disease (e.g., uncontrollable arrhythmia/angina, cardiac failure) 6.Patients with uncontrollable diabetes mellitus concurrently 7.Patients with active double cancer 8.Patients with any clinically problematic psychiatric disorder 9.Patients with untreated fracture (except compression fracture associated with osteoporosis) or severe wound 10.Pregnant, lactating or possibly pregnant female patients, or patients reluctant to take an effective contraceptive measure 11.Patients have immuno-checkpoint inhibitor as previous treatment 12.Other patients who, in the opinion of the investigator, are not eligible for participation in the present study for any reason
研究者
相似试验
招募中
2 期
The R- 100 ITP Study : evaluating the efficacy of a single weekly dose of 100mg of Rituximab over 4 weeks in patients with refractory or relapsing idiopathic thrombocytopaenic purpuraIdiopathic thrombocytopaenic purpuraBlood - Haematological diseasesACTRN12612000591853Florence Peterson Fund50
进行中（未招募）
1 期
DALY II USA/MB-CART2019.1 for DLBCCTIS2023-508508-39-01Miltenyi Biomedicine GmbH110
进行中（未招募）
1 期
A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemiaCytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemiaMedDRA version: 21.1Level: LLTClassification code: 10066110Term: T-cell lymphoblastic leukemia acute Class: 10029104CTIS2023-507899-47-00Goethe University Frankfurt40
进行中（未招募）
1 期
Research study to determine whether a drug called obinutuzumab given to persons with relapsed and refractory Waldenström Macroglobulinemia in induction therapy followed by two years of maintenance is safe and efficacious.EUCTR2016-005053-20-PLPolish Myeloma Consortium30
进行中（未招募）
1 期
Clinical study aimed to assess in patients with triple-negative operable breast cancer the activity of the drug zoledronate administered before surgery, according to the the tumor aggressiveness (determined by the level of expression of the p53 protein)ewly diagnosed, untreated, operable triple negative breast cancerMedDRA version: 18.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004194-16-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI21